Sunday, Aug 09, 2020 | Last Update : 08:41 PM IST

138th Day Of Lockdown

Maharashtra49026232728117092 Tamil Nadu2850242275754690 Andhra Pradesh2170401296151939 Karnataka164924842322998 Delhi1441271293624098 Uttar Pradesh118038698332028 West Bengal89666630601954 Telangana7751354330615 Bihar7578648673419 Gujarat68855517922604 Assam5549737225132 Rajasthan5065636310776 Odisha4419328698307 Haryana4005433444467 Madhya Pradesh3729827621962 Kerala3312020862107 Jammu and Kashmir2439020862459 Punjab2193014040539 Jharkhand165427503154 Chhatisgarh11408831987 Uttarakhand89015731112 Goa7947559570 Tripura6014408437 Puducherry5123291475 Manipur3635192711 Himachal Pradesh3242201513 Nagaland26888937 Arunachal Pradesh204913263 Chandigarh137482023 Meghalaya10234236 Sikkim8544061 Mizoram5672890
  Business   Companies  14 Jun 2020  Dr Reddy's inks licensing pact with Gilead Sciences for Remdesivir

Dr Reddy's inks licensing pact with Gilead Sciences for Remdesivir

ANI
Published : Jun 14, 2020, 9:59 am IST
Updated : Jun 14, 2020, 9:59 am IST

Gilead Sciences signed similar non-exclusive licensing agreements with Cipla, Hetero Labs, Jubilant Lifesciences, Mylan and Zydus Cadila

 Dr Reddy’s signs deal with Gilead to register, manufacture and sell Remdesivir in India. (ANI Photo)
  Dr Reddy’s signs deal with Gilead to register, manufacture and sell Remdesivir in India. (ANI Photo)

Hyderabad: Dr Reddy's Laboratories said on Saturday it has entered into a non-exclusive licensing agreement with Gilead Sciences Inc that will grant Dr Reddy's the right to register, manufacture and sell Gilead's investigational drug Remdesivir, a potential treatment for Covid-19 in 127 countries including India.

Dr Reddy's will receive technology transfer from Gilead for manufacturing of this drug. It will need to do the manufacturing scale up and obtain regulatory approval for marketing of this drug in respective countries.

 

Gilead Sciences has signed similar non-exclusive voluntary licensing agreements with Cipla, Hetero Labs, Jubilant Lifesciences, Mylan and Zydus Cadila. All these licences are royalty-free until the World Health Organisation declares the world free from coronavirus pandemic, or a drug or vaccine is approved against the deadly virus.

Remdesivir, an investigational anti-viral therapy developed by Gilead, has received emergency use authorisation by the US Food and Drug Administration (USFDA) to treat Covid-19.

On June 1, the Drug Controller General of India (DCGI) granted the marketing authorisation to Gilead Sciences' anti-viral drug remdesivir injection 5 mg/mL and Remdesivir lyophilised powder for injection 100 mg for the treatment of suspected or laboratory-confirmed coronavirus disease 2019 (Covid-19) in adults and children hospitalised with severe disease.

 

Tags: hyderabad, dr reddys labs, licensing agreement, gilead sciences inc, remdesivir, covid-19
Location: India, Telangana, Hyderabad